NCT06228014

Brief Summary

The goal of this observational prospective and analytical study is to validate that the device is a valid tool for improving the adequacy of referrals to dermatology. As a secondary objectives the investigators set out to validate that the device reduces costs in secondary care; to validate that the device reduces dermatology waiting lists and to validate that the device optimizes clinical flow in Osakidetza. The primary care physician will explain to the patient what his/her participation in the study will consist of by means of the Patient Information Sheet. The patient, in turn, will be able to ask all the questions he/she considers appropriate in order to clarify all his/her doubts regarding the study. If the patient wishes to participate in the study, he/she will sign the Informed Consent Form and will be assigned a study code. After signing the informed consent, the data collection process begins. The Principal Investigator and/or collaborating investigators assigned to this task will collect demographic data (age, sex) and data related to the diagnosis, characteristics and treatment of the pathology. Primary care physicians should take photographs showing the areas affected by the pathology. These photographs will be taken with their own smartphone or using a mobile dermatoscope if the use of a mobile dermatoscope is clinically relevant. The primary care physician, will record the photographs periodically, uploading the images to a Google Drive folder that the study sponsor will enable at the beginning of the study. The photographs are named using a code that includes the patient ID (NNN) and photograph number (nn). Primary care physicians will assess the patient\'s pathology as they would in a routine consultation and record their diagnosis and referral criteria, and associate them with the patient\'s photographs and demographic data to be collected by the research team telematically at the end of the study duration. These information transfers and the storage of the photographs will be in line with the European Regulation 2016/679 of 27 April on the protection of natural persons with regard to the processing of personal data and the free movement of such data and the Organic Law 3/2018 of 5 December on the Protection of Personal Data and guarantee of digital rights. The specialist physicians will have a period of one month after the end of the recruitment period to evaluate and label the photographs taken. In this labeling process they will record their diagnosis, and whether they consider that the referral has been appropriate or not. This information will be collected by the research team telematically at the end of the study duration. This transfer of information and storage of the photographs will comply with European Regulation 2016/679, of 27 April, on the protection of natural persons with regard to the processing of personal data and the free movement of such data and with Organic Law 3/2018, of 5 December, on the Protection of Personal Data and guarantee of digital rights.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 23, 2022

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

January 19, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 29, 2024

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 6, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 6, 2025

Completed
Last Updated

January 16, 2026

Status Verified

January 1, 2026

Enrollment Period

2.5 years

First QC Date

January 19, 2024

Last Update Submit

January 15, 2026

Conditions

Keywords

DermatologyGeneral practitionersArtificial IntelligenceAlgorithmDiagnostic

Outcome Measures

Primary Outcomes (1)

  • Number of patients with inappropriate referrals

    We define an inappropriate referral as one that, according to the criteria of the specialists consulted in the study, does not require the attention of a dermatologist in order to be treated, as may be the case of seborrheic keratosis. For this purpose, a photograph will be taken and the date of the patient's visit to the clinic and the criteria for moving to the next stage of the care process will be recorded

    The moment of enrollment

Secondary Outcomes (5)

  • Demographical Data

    The moment of enrollment

  • Data on the primary care physician

    The moment of enrollment

  • Cost reduction

    The moment of enrollment

  • Waiting list reduction

    The moment of enrollment

  • Clinical data

    The moment of enrollment

Study Arms (1)

Patients with any kind of skin pathologies

Adult patients (≥ 18 years) with skin pathologies seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals. Patients participating in this study did not receive any specific treatment as part of the research protocol. Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (≥ 18 years) with any kind of skin pathology seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals.

You may qualify if:

  • Patients with skin pathologies.
  • Patients aged 18 years or older.
  • Patients who have signed the informed consent for the study.

You may not qualify if:

  • Patient who at the investigator\'s discretion will not comply with the study procedures.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Cruces

Barakaldo, Biscay, 48903, Spain

Location

MeSH Terms

Conditions

Skin DiseasesDisease

Condition Hierarchy (Ancestors)

Skin and Connective Tissue DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 19, 2024

First Posted

January 29, 2024

Study Start

November 23, 2022

Primary Completion

May 6, 2025

Study Completion

May 6, 2025

Last Updated

January 16, 2026

Record last verified: 2026-01

Locations